On May 24, in an official ceremony in Sofia, for another year the Ministry of Education and Science granted the awards for significant contributions and achievements in scientific development – “Pythagoras”.
Pythagoras Award 2021 in the category “Company with the biggest investments in scientific research and development” for the period 2017-2019 was awarded to Comac Medical Ltd. According to the jury, after a rivalled competition, the company has distinguished itself and met the high criteria for a prize in this area.
The award was received by the owner and CEO of Comac Medical, Dr. Milen Vrabevski.
“This is the second time I receive this award and I am extremely grateful that you all give me the opportunity and motivation to continue in this direction. Most of my gratitude goes to my colleagues who carried on their shoulders the whole process of continuous investment and reinvestment in Bulgarian science. It is very important to emphasize the following: “Dear colleagues, this award is yours”, said Dr. Vrabevski during the award ceremony and noted that by constant investment in innovative thinking, he and his team achieved some extraordinary results, and an example of this is the vaccination of the citizens of the Republic of Northern Macedonia that started on his initiative.
The Pythagoras Award goes to Comac Medical for second time after the company won the prize in the same category in 2016. The company demonstrates an accelerated rate of increase in its investments in scientific activities, and as a result of this favorable dynamics, the funds invested in scientific R&D by 2020, compared to 2016, have doubled.
Comac Medical was established in 1997 by Dr. Milen Vrabevski, owner and CEO of the company. Over the years, Comac Medical has proven itself as the largest company for research and development investments in Southeast Europe, conducting both traditional and highly innovative clinical studies in various therapeutic areas and in projects for improving patients’ quality of life.
In 2021, Comac Medical operates in 30 countries. The company reinvests 88% of its net sales revenue in scientific R&D investments. The company’s costs for the cumulative three-year period (2018-2020) amount to BGN 62,324,000 – significant funds with absolute value for the scale of the country.
Over the last five years, the company has placed a specific focus on finding innovative solutions of health and social challenges, including through Horizon 2020 program, on forward thinking towards personalized medicine and on creating specialized knowledge about lung diseases that are as equally important as the oncological and cardiovascular diseases.